BR0007999A - Combinação de droga não-interativa, formulação farmacêutica, embalagem farmacêutica, e, uso de ácido (e) - 7 - [4- (4-fluorofenil) -6-isopropil-2- [metil(metilsulfonil) amino] pirimidin-5-il] (3r, 5s) - 3,5-diidroxihept-6-enóico, ou um sal farmaceuticamente aceitável do mesmo - Google Patents
Combinação de droga não-interativa, formulação farmacêutica, embalagem farmacêutica, e, uso de ácido (e) - 7 - [4- (4-fluorofenil) -6-isopropil-2- [metil(metilsulfonil) amino] pirimidin-5-il] (3r, 5s) - 3,5-diidroxihept-6-enóico, ou um sal farmaceuticamente aceitável do mesmoInfo
- Publication number
- BR0007999A BR0007999A BR0007999-5A BR0007999A BR0007999A BR 0007999 A BR0007999 A BR 0007999A BR 0007999 A BR0007999 A BR 0007999A BR 0007999 A BR0007999 A BR 0007999A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- enoic
- amino
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 230000002452 interceptive effect Effects 0.000 title abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title abstract 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000009512 pharmaceutical packaging Methods 0.000 title abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 abstract 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000890 drug combination Substances 0.000 abstract 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 abstract 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 abstract 1
- 108010044467 Isoenzymes Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229940125753 fibrate Drugs 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9902593.4A GB9902593D0 (en) | 1999-02-06 | 1999-02-06 | Drug combinations |
| GBGB9921064.3A GB9921064D0 (en) | 1999-09-08 | 1999-09-08 | Drug combination |
| GBGB9921063.5A GB9921063D0 (en) | 1999-09-08 | 1999-09-08 | Therapy |
| PCT/GB2000/000278 WO2000045817A1 (en) | 1999-02-06 | 2000-02-01 | Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0007999A true BR0007999A (pt) | 2001-11-06 |
Family
ID=27269637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0007999-5A BR0007999A (pt) | 1999-02-06 | 2000-02-01 | Combinação de droga não-interativa, formulação farmacêutica, embalagem farmacêutica, e, uso de ácido (e) - 7 - [4- (4-fluorofenil) -6-isopropil-2- [metil(metilsulfonil) amino] pirimidin-5-il] (3r, 5s) - 3,5-diidroxihept-6-enóico, ou um sal farmaceuticamente aceitável do mesmo |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US6982157B1 (enExample) |
| EP (1) | EP1185274B1 (enExample) |
| JP (2) | JP2002536331A (enExample) |
| KR (2) | KR20060117381A (enExample) |
| CN (1) | CN1165310C (enExample) |
| AR (1) | AR029333A1 (enExample) |
| AT (1) | ATE282415T1 (enExample) |
| AU (1) | AU767304B2 (enExample) |
| BR (1) | BR0007999A (enExample) |
| CA (1) | CA2358632C (enExample) |
| CZ (1) | CZ301296B6 (enExample) |
| DE (1) | DE60015965T2 (enExample) |
| EE (1) | EE04929B1 (enExample) |
| EG (1) | EG23858A (enExample) |
| ES (1) | ES2232418T3 (enExample) |
| GB (1) | GB0000710D0 (enExample) |
| ID (1) | ID30485A (enExample) |
| IL (1) | IL144715A0 (enExample) |
| IS (1) | IS2337B (enExample) |
| MX (1) | MXPA01007905A (enExample) |
| MY (1) | MY130606A (enExample) |
| NO (1) | NO320745B1 (enExample) |
| NZ (1) | NZ512982A (enExample) |
| PL (1) | PL198034B1 (enExample) |
| PT (1) | PT1185274E (enExample) |
| TR (1) | TR200102228T2 (enExample) |
| TW (1) | TWI282738B (enExample) |
| WO (1) | WO2000045817A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| BRPI0206641B8 (pt) | 2001-01-26 | 2021-05-25 | Merck Sharp & Dohme | uso de um inibidor da absorção de esteróis |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| SK288217B6 (sk) | 2001-01-26 | 2014-08-05 | Merck Sharp & Dohme Corp. | Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| DE60216300T2 (de) | 2001-09-21 | 2007-06-28 | Schering Corp. | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| AU2003291719A1 (en) | 2002-11-06 | 2004-06-03 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| ES2311806T3 (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| CA2517573C (en) | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| CN1756756A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
| JP5069001B2 (ja) | 2003-10-10 | 2012-11-07 | ベロクシス ファーマシューティカルズ エー／エス | フィブラートを含む固体投与形態 |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AU2005271413A1 (en) | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
| EP1948600B1 (en) * | 2005-07-05 | 2014-04-16 | The President & Fellows Of Harvard College | Liver targeted conjugates |
| EP1968593B1 (en) * | 2005-12-20 | 2017-08-23 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid |
| US20080109252A1 (en) * | 2006-11-08 | 2008-05-08 | Lafountain Andrea | Predicting patient compliance with medical treatment |
| US20120130202A1 (en) * | 2010-11-24 | 2012-05-24 | Fujitsu Limited | Diagnosis and Monitoring of Musculoskeletal Pathologies |
| CN112955965B (zh) * | 2018-06-14 | 2024-04-09 | 阿斯利康(英国)有限公司 | 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法 |
| US20220273652A1 (en) | 2019-07-31 | 2022-09-01 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate |
| WO2024223797A1 (en) | 2023-04-28 | 2024-10-31 | Institut National de la Santé et de la Recherche Médicale | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| DK0521417T3 (da) * | 1991-07-02 | 1995-03-27 | Benckiser Gmbh Joh A | Sammenklappelig forrådsflaske |
| JP3852621B2 (ja) * | 1992-01-21 | 2006-12-06 | あすか製薬株式会社 | 血管内皮細胞機能改善剤 |
| FR2730231B1 (fr) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
| KR20010031501A (ko) * | 1997-10-31 | 2001-04-16 | 추후제출 | 5-알파 환원효소 활성을 조절하는 방법 및 조성물 |
-
2000
- 2000-01-14 GB GBGB0000710.4A patent/GB0000710D0/en not_active Ceased
- 2000-02-01 DE DE60015965T patent/DE60015965T2/de not_active Expired - Lifetime
- 2000-02-01 KR KR1020067021986A patent/KR20060117381A/ko not_active Ceased
- 2000-02-01 TR TR2001/02228T patent/TR200102228T2/xx unknown
- 2000-02-01 IL IL14471500A patent/IL144715A0/xx not_active IP Right Cessation
- 2000-02-01 EE EEP200100406A patent/EE04929B1/xx unknown
- 2000-02-01 ID IDW00200101892A patent/ID30485A/id unknown
- 2000-02-01 NZ NZ512982A patent/NZ512982A/en not_active IP Right Cessation
- 2000-02-01 CA CA002358632A patent/CA2358632C/en not_active Expired - Fee Related
- 2000-02-01 US US09/889,414 patent/US6982157B1/en not_active Expired - Lifetime
- 2000-02-01 AU AU21218/00A patent/AU767304B2/en not_active Expired
- 2000-02-01 MX MXPA01007905A patent/MXPA01007905A/es not_active IP Right Cessation
- 2000-02-01 BR BR0007999-5A patent/BR0007999A/pt not_active Application Discontinuation
- 2000-02-01 JP JP2000596937A patent/JP2002536331A/ja active Pending
- 2000-02-01 PT PT00901264T patent/PT1185274E/pt unknown
- 2000-02-01 PL PL364780A patent/PL198034B1/pl unknown
- 2000-02-01 ES ES00901264T patent/ES2232418T3/es not_active Expired - Lifetime
- 2000-02-01 WO PCT/GB2000/000278 patent/WO2000045817A1/en not_active Ceased
- 2000-02-01 CN CNB008034702A patent/CN1165310C/zh not_active Expired - Lifetime
- 2000-02-01 KR KR1020017009914A patent/KR20010101790A/ko not_active Ceased
- 2000-02-01 AT AT00901264T patent/ATE282415T1/de active
- 2000-02-01 EP EP00901264A patent/EP1185274B1/en not_active Expired - Lifetime
- 2000-02-01 CZ CZ20012844A patent/CZ301296B6/cs not_active IP Right Cessation
- 2000-02-04 AR ARP000100507A patent/AR029333A1/es unknown
- 2000-02-04 MY MYPI20000416A patent/MY130606A/en unknown
- 2000-02-22 EG EG20000124A patent/EG23858A/xx active
- 2000-05-11 TW TW089102105A patent/TWI282738B/zh not_active IP Right Cessation
-
2001
- 2001-07-17 IS IS6009A patent/IS2337B/is unknown
- 2001-08-03 NO NO20013811A patent/NO320745B1/no not_active IP Right Cessation
-
2005
- 2005-03-15 US US11/079,530 patent/US20060040969A1/en not_active Abandoned
-
2007
- 2007-07-27 JP JP2007195798A patent/JP2007277267A/ja active Pending
-
2008
- 2008-09-29 US US12/285,117 patent/US20090042911A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0007999A (pt) | Combinação de droga não-interativa, formulação farmacêutica, embalagem farmacêutica, e, uso de ácido (e) - 7 - [4- (4-fluorofenil) -6-isopropil-2- [metil(metilsulfonil) amino] pirimidin-5-il] (3r, 5s) - 3,5-diidroxihept-6-enóico, ou um sal farmaceuticamente aceitável do mesmo | |
| CR10114A (es) | Composiciones farmacéuticas que comprenden inhibidoras de la hmg coa reductasa (divisional del exp. 6687) | |
| MY134902A (en) | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia | |
| NO20013994D0 (no) | Fremgangsmate for fremstilling av tert-butyl (E)-(6[2-[4-(4- fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]vinyl](4R,6S)-2,2-dimetyl[1,3]dioksan-4-yl)acetat | |
| PE20001225A1 (es) | Derivados de adenina | |
| GEP20032996B (en) | Combinations of Protein Farnesyltransferase and HMG CoA Reductase Inhibitors, Pharmaceutical Compositions and Methods for Treatment | |
| WO2010030201A3 (en) | Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid | |
| BR0007991A (pt) | Uso do composto ácido (e) -7- [ 4- (4-fluorofenil) -6-isopropil-2- [metil (metilsulfonil) amino] pirimidin -5-il] - (3r, 5s) -3,5-diidroxiept-6-enóico, ou de um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de preparação de uma composição farmacêutica, de redução dos nìveis de c-ldl e da razão de lipìdeo de c-ldl/ c-hdl, e, regime dosagem | |
| EA200801447A1 (ru) | Фармацевтическая композиция | |
| BR0208814A (pt) | Uso de derivados de ariletenossulfonamida | |
| SI1185274T1 (en) | Drug combinations comprising (e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 | |
| HUP0104977A2 (hu) | (E)-7-[4-(4-fluor-fenil)-6-izopropil-2-(metil-/metilszulfonil/-amino)-pirimidin-5-il]-(3R,5S)-3,5-dihidroxi-6-hepténkarbonsavat és egy P450 3A4 izoenzim-inhibítort, -indukálószert vagy szubsztrátumot tartalmazó gyógyszerkombináció | |
| UY30336A1 (es) | Composiciones farmacéuticas conteniendo ácido (e)-7-(4-(4-fluorofenil)-6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)-(3r,5s)-3,5-dihidroxihept-6-enoico y sales farmacéuticamente aceptables de la misma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O E 13 DA LPI. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |